Funded Biotechnology Startups in Los Angeles
Los Angeles has produced a range of biotechnology funding events spanning seed rounds through post-IPO equity raises.
Los Angeles has produced a range of biotechnology funding events spanning seed rounds through post-IPO equity raises. Among the 25 most recent rounds on record, deal sizes run from Force Impact Technologies' $100K in September 2020 to ACELYRIN's $300M Series C in September 2022. The majority of companies sit in earlier or ambiguous stages — a large share of rounds are labeled Series Unknown or carry no stage designation — which reflects both the opacity common in biotech financing and the relative youth of many LA-based firms.
Recent years show continued deal flow: eleven rounds closed in 2024 or 2025, including Rarity PBC's $5M seed in October 2025, Dyania Health's $10M Series A in October 2024, and Advanced Bifurcation Systems' $21M raise in January 2025. Two publicly traded companies, ChromaDex and Puma Biotechnology, also appear with Post-IPO Equity rounds from 2022, adding a later-stage dimension to the otherwise early-to-mid-stage mix.
Most recent rounds
25 shownRelated listings
Frequently asked
What are the largest disclosed rounds among LA biotech companies in this dataset?
ACELYRIN leads with a $300M Series C closed in September 2022. Octant Bio raised an $80M Series B in April 2022, and Appia Bio closed a $52M round in May 2021. After those three, the next largest is Advanced Bifurcation Systems at $21M in January 2025, with most other disclosed rounds falling below $25M.
How much recent funding activity is visible in 2024 and 2025?
Eleven of the 25 rows date to 2024 or 2025. 2025 entries include MyoGene Bio ($400K venture round, November), Rarity PBC ($5M seed, October), Advanced Bifurcation Systems ($21M, January), and Kairos Pharma ($4M, January). 2024 activity includes Dyania Health's $10M Series A, Capricor Therapeutics at $15M, and Immix Biopharma at $15M.
Which companies here are at seed stage and what are typical round sizes?
Four companies raised labeled seed rounds: Rarity PBC ($5M, October 2025), Partillion Bioscience ($5M, September 2023), Sequencing.com ($5M, November 2022), and PathoGene ($500K, July 2021). The three larger seed rounds all landed at exactly $5M, while PathoGene's $500K sits well below that cluster.
Are any companies in this list publicly traded or post-IPO?
Yes — ChromaDex and Puma Biotechnology both show Post-IPO Equity rounds, both from 2022. ChromaDex raised $3M in October 2022 and Puma Biotechnology raised $10M in March 2022, indicating continued capital market activity from already-public LA biotech companies.
How many rounds in this dataset have undisclosed or ambiguous amounts?
At least five rows either list the amount as undisclosed (9 Dots, Dalton Bioanalytics, Forcyte Biotechnologies) or have no round type label at all (Mozza, Appia Bio, Force Impact Technologies). This is a notable share of the 25 records, meaning deal value is only partially visible for this segment.
Which later-stage rounds are present, and how does ACELYRIN compare to peers?
Series B rounds appear for Octant Bio ($80M) and Nammi Therapeutics ($1M), showing wide variance even within the same stage. ACELYRIN's $300M Series C is the only Series C in the dataset and roughly 3.75x the size of Octant Bio's Series B, making it a clear outlier in this Los Angeles cohort.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.